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ABSTRACT
Owing to the dynamic nature of the transcriptome, gene expression proﬁling is a promising
tool for discovery of disease-related genes and biological pathways. In the present study, we
examined gene expression in whole blood of 12 patients with CAD (coronary artery disease) and
12 healthy control subjects. Furthermore, ten patients with CAD underwent whole-blood gene
expressionanalysisbeforeandafterthecompletionofacardiacrehabilitationprogrammefollowing
surgical coronary revascularization. mRNA and miRNA (microRNA) were isolated for expression
proﬁling. Gene expression analysis identiﬁed 365 differentially expressed genes in patients with
CAD compared with healthy controls (175 up- and 190 down-regulated in CAD), and 645
in CAD rehabilitation patients (196 up- and 449 down-regulated post-rehabilitation). Biological
pathway analysis identiﬁed a number of canonical pathways, including oxidative phosphorylation
and mitochondrial function, as being signiﬁcantly and consistently modulated across the groups.
Analysis of miRNA expression revealed a number of differentially expressed miRNAs, including
hsa-miR-140-3p (control compared with CAD, P=0.017), hsa-miR-182 (control compared with
CAD, P=0.093), hsa-miR-92a and hsa-miR-92b (post- compared with pre-exercise, P<0.01).
Global analysis of predicted miRNA targets found signiﬁcantly reduced expression of genes with
targetregionscomparedwiththosewithout:hsa-miR-140-3p(P=0.002),hsa-miR-182(P=0.001),
hsa-miR-92a and hsa-miR-92b (P=2.2×10−16). In conclusion, using whole blood as a ‘surrogate
tissue’ in patients with CAD, we have identiﬁed differentially expressed miRNAs, differentially
regulated genes and modulated pathways which warrant further investigation in the setting of
cardiovascular function. This approach may represent a novel non-invasive strategy to unravel
potentially modiﬁable pathways and possible therapeutic targets in cardiovascular disease.
INTRODUCTION
CAD (coronary artery disease) is caused by multiple
genetic and environmental factors and the interaction
between them. Microarray analysis is a powerful
technique for high-throughput global transcriptomic
proﬁling of gene expression. In addition to identifying
newtargetgenes,thismethodalsoallowstheclusteringof
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genes according to similar patterns of expression and/or
function from which gene expression ﬁngerprints can
be created. Gene expression ﬁngerprints have become
a useful tool in research and diagnosis, with multiple
applications, for example in the classiﬁcation of different
tumour types [1], in deﬁning the molecular pathogenesis
of segmental glomerulosclerosis [2] in and detecting
exposure to toxic substances [3].
Microarray studies of human disease are often limited
by challenges in obtaining human tissues and by
the lack of models that effectively capture clinically
relevant disease features. Peripheral blood has become an
attractive prime tissue for biomarker detection because
of its critical role in immune response, metabolism,
communication with cells and the extracellular matrix
in almost all tissues and organs in the human body, as
well as for the simplicity of sample collection [4–6]. The
dynamic and interactive properties of blood give rise
to the possibility that subtle changes occurring within
the body, such as changes in association with a disease
process or in response to an injury, may leave ‘footprints’
inblood.Thereforetranscriptionalproﬁlingfromwhole-
bloodcellsmightprovideanalternativetotissuebiopsyin
the search for biomarker genes of cardiovascular disease
[7].
miRNAs (microRNAs) are small non-coding RNAs
that bind mRNAs at their 3 -UTRs (untranslated
regions), stimulating mRNA degradation or inhibiting
protein translation [8]. Many miRNAs are up-regulated
in response to cellular stress [9] and can modify essential
cellular functions of proliferation, differentiation and
programmed death [10–12]. Evidence indicates that
miRNAs are also implicated in cardiovascular disease
[13–15] and have the capacity to create cardiac pathology
[16–18].
Given that miRNAs respond to acute changes in cell
stress,wehypothesizedthatcombininginformationfrom
whole-blood miRNA proﬁles and mRNA signatures
could improve the knowledge about the pathogenesis
of cardiovascular disease. We examined this notion
through comprehensive analyses of miRNA and mRNA
expression levels in whole blood from patients affected
by severe CAD, also attending a cardiac rehabilitation
programme, in comparison with healthy subjects.
MATERIALS AND METHODS
Patients
Patients undergoing elective CABG (coronary artery
bypass graft) surgery (n=163) at the Western Inﬁrmary,
Glasgow, U.K. were enrolled between October 2006
and August 2008. These patients attended our clinical
investigation unit 1 day before surgery. Control subjects
(n=63) were recruited by placing an advertisement
in the University of Glasgow Newsletter and in local
sport centres. Although ethical and funding limitations
prevented angiographic investigation of these individuals
to absolutely discount the presence of CAD, these
subjectspresentedashealthyatrecruitmentandwerefree
ofanyevidenceofCADaccordingtotheirpatienthistory.
Related studies [19–21] from our group have shown that
our healthy control subjects present with normal ECG
and no history of arterial hypertension, angina, CAD or
peripheral artery disease. Furthermore, we have shown
that control subjects have better aortic compliance and
lower levels of vascular ROS (reactive oxygen species).
At 4–6 weeks after the CABG procedure, 37 out of the
163 patients were also included in a cardiac rehabilitation
programme, consisting of 60 min exercise (15 min warm-
ing up, 30 min cardiovascular training and 15 min
warmingdown),twiceaweekfor10 weeks.Theinitial4–
6-weekperiodfollowingsurgerywastoallowthepatients
to recover from the procedure to a degree where they
were well enough to commence exercise, and also would
allow some of the more acute responses to surgery (e.g.
increases in inﬂammatory markers) to subside. Although
some markers remained elevated [e.g. CRP (C-reactive
protein)], this difference was not found to be signiﬁcant
with regard to control subjects. The exercise regimen
was adapted to each individual’s exercise capacity,
assessed by validated step and walking tests [19,22,23]
at inclusion and after completion of the rehabilitation
programme. For microarray analysis, we selected
12 subjects with severe CAD and 12 control subjects;
and ten patients attending the exercise programme
examinedbeforeandafteritscompletion.Detailsofthese
patients are given in Supplementary Tables S1 and S2 (at
http://www.clinsci.org/cs/119/cs1190335add.htm).
The study complies with the Declaration of Helsinki
and was approved by the local ethics committee. All
participants gave written informed consent and used a
standardizedquestionnairetoself-reportthehealthstatus
and medication taken.
Blood collection and RNA isolation
Venous blood samples were drawn via antecubital
venipuncture from each subject in a sitting position
after fasting for 3 h, and routine biochemistry was
assessed in plasma. An aliquot of whole blood (2.5 ml)
for each subject was collected directly into PAXgene
blood RNA tubes (PreAnalytiX) and stored at −20◦C
within 24 h before RNA extraction. After collection
of all samples, total RNA was isolated using the
PAXgene blood RNA kit (PreAnalytiX), according to
the manufacturer’s protocol, and subjected to on-column
DNase I treatment with RNase-free Dnase (Qiagen).
RNA quantity and quality were determined using a
NanoDrop Technologies ND-1000 spectrophotometer
and an Agilent 2100 bioanalyser. A total of 400 ng
of RNA (with an RNA integrity number >7.5) was
used to generate cDNA (Illumina TotalPrep RNA
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Ampliﬁcation kit; Ambion). Reverse transcription with
T7 oligo(dT) primers was used to produce ﬁrst-strand
cDNA. The cDNA then underwent second-strand
synthesisandRNAdegradationbyDNApolymeraseand
RNase H, followed by clean up. In vitro transcription
technology, along with biotin UTP, was employed to
generate multiple copies of biotinylated cRNA. The
labelled cRNA was puriﬁed using a ﬁlter cartridge and
quantiﬁed using a NanoDrop Technologies ND-1000
spectrophotometer.TheintegrityofcRNAwasevaluated
using an Agilent 2100 bioanalyser.
Small RNA species (including miRNA) were also
extracted by modifying the PAXgene procedure by
harvesting the ﬂow-thorough of the PAXgene RNA
column, and isolated using the miRNeasy Mini Kit
(Qiagen), according to the manufacturers’ protocols.
Successful isolation of small RNAs was conﬁrmed using
Agilent 2100 bioanalyser analysis.
All mRNA and miRNA expression studies were
performed on samples from individual patients (not
pooled).
Microarray analysis
Microarray analysis of gene expression was performed
on the Illumina Beadstation platform, using Illumina
Sentrix humanref-6 beadchips. Labelled cRNA (1.5 μg)
was used for hybridization to the array, according to
the manufacturer’s protocol. A maximum of 10 μlo f
cRNAwasmixedwith20 μlofGEX-HYBhybridization
solution. The pre-heated 30 μla s s a ys a m p l ew a s
dispensed on to each array and incubated for 18 h at
58◦C. Following hybridization, samples were washed
and scanned with a BeadArray Reader (Illumina).
All data passed quality control analysis as assessed
by the Illumina on-board software (BeadStudio 3.4)
and Principle Component Analysis (Partek Genomics
Suite). Quantile normalization of gene expression was
performed (BeadStudio 3.4), and differential expression
was determined by Rank Products analysis [24], where a
5% FDR (false discovery rate) cut-off value was used.
Rank Products is a simulation method based on the
average rank each gene has for a pairwise comparison
difference compared with what would be expected under
the null hypothesis of no differential expression. It has
beenspeciﬁcallydevelopedfortheanalysisofmicroarray
experiments and was shown to be more powerful than
Student’s t tests [25]. In addition, in a comparison of
11 different methods for microarray analysis [26], Rank
Productswasshowntohaveperformedwell,inparticular
with small sample sizes. Signiﬁcance was assessed using
the FDR multiple testing correction method [27] with
an FDR cut-off of 10% (gene expression) or 5%
(miRNA expression). For probe sets with an FDR
>10%, a further 1000 permutations were carried out to
obtain more precise P values and FDR values. Molecular
interactions between genes were mapped to common
canonical pathways using the Pathway Explorer function
within Ingenuity Pathway Analysis software (Ingenuity
Systems; www.ingenuity.com).
miRNA microarray analysis was performed to de-
termine differential expression in blood-borne miRNAs
between (i) healthy individuals and patients with
CAD (n=7), and (ii) patients with CAD before a
cardiac rehabilitation exercise programme and at 6 weeks
after exercise (n=8). All miRNA expression proﬁling
was carried out by LC Sciences using a proprietary
microﬂuidic array (Chip ID miRHuman_11.0_080411)
based on the Sanger miRBase v11.0 database
(http://www.sanger.ac.uk/Software/Rfam/mirna/), de-
signed to detect 887 human miRNAs. Proprietary
analysis employed a Student’s t test to compare data.
An α level of 10% was accepted for the Student’s t test
analysis in order to identify sufﬁcient targets for further
evalulation. miRNA data were subsequently re-analysed
in-house using the Ranked Products method with an
FDR value of 5% [24]. miRNAs achieving signiﬁcance
under both analyses, and which had a signal intensity
>500 ﬂuorescence units, were considered for further
analysis.
Bioinformaticdeterminationofdownstreampredicted
targets for candidate miRNAs was performed as
described previously by Selbach et al. [28]. Brieﬂy,
an unbiased search for sequence motifs (representing
positions 2–7 of the miRNA seed region) in a library of
genome-wide3 -UTRsinhumanwasundertakenforeach
miRNA.Onthisbasisgeneswereassignedtoeithertarget
gene or non-target groups. Gene expression was then
compared between patients with CAD and controls, and
patients with CAD pre- and post-exercise respectively,
for gene targets and non-targets, and compared with
unpaired (CAD compared with controls) or paired
(post- compared with pre-exercise) Student’s t tests
(P<0.05).
qRT-PCR (quantitative real-time PCR)
analysis
qRT-PCR was performed to validate changes in selected
genesbyIPAsoftware.PuriﬁedRNAwasconvertedinto
cDNA using TaqMan® reverse transcription reagents in
a total reaction volume of 20 μl (Applied Biosystems)
containing: 10×TaqMan® reverse transcription buffer
(2.0 μl), 25 nM MgCl2 (4.4 μl), deoxyNTPs (4.0 μl),
random hexamers (1.0 μl), RNase inhibitor (0.4 μl)
and MultiScribe reverse transcriptase (0.5 μl), using the
following cycling parameters: 25◦C for 10 min, 48◦C
f o r3 0 m i na n dt h e n9 5 ◦C for 5 min. Appropriate ‘no
template’ qRT-PCR controls were processed similarly.
cDNA was diluted to a ﬁnal volume of 80 μl by addition
of nuclease-free water and stored at −20◦C until use.
qRT-PCR was performed in 5 μl volumes, in a reaction
buffer containing 2.5 μlo f2×TaqMan® Universal PCR
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Master Mix, 2 μl of cDNA template and 0.25 μl of each
TaqMan® probe/primer mixture (Supplementary Table
S3 at http://www.clinsci.org/cs/119/cs1190335add.htm).
Ampliﬁcation reactions were performed in triplicate,
duplexed with GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) as an endogenous control. Assay plates
were sealed, vortex-mixed, centrifuged (1 min at 850 g),
and subjected to PCR (ABI Sequence Detection System
7900HT),usingABI-suggestedcyclingparameters:50◦C
for 2 min, 95◦C for 10 min and then 40 cycles of 95◦C
f o r1 5s ,f o l l o w e db y6 0◦C for 1 min. Data were exported
using a 0.2 threshold, with 3–15 cycles set as baseline.
Cycle threshold (Ct) values were normalized by the
geometric means of GAPDH. Triplicates were averaged
to calculate an expression value for each sample.
Statistical analysis
UsingthepowercalculationmethoddescribedbyPounds
and Cheng [29], a desired FDR of 0.05, a desired average
power of 80% and assuming that 30 out of 833 miRNAs
tobeinvestigatedhaveaθ valueof1.8(withtheremainder
being assumed not to be differentially expressed), we
calculatedthataasamplesizeof12pergroupwasneeded.
Statistical analyses were performed using GraphPad
Prism software. Values are expressed as means+ −S.D.
Paired or unpaired Student’s t tests were used to
comparedataasappropriate.APvalue<0.05(two-sided)
was considered signiﬁcant. For analysis of microarray
expression data, a Ranked Products approach was used,




(n=12), we identiﬁed 365 differentially expressed genes:
175 genes were up-regulated and 190 genes were down-
regulated. In patients with CAD studied across an
exercise rehabilitation programme (n=10), we found
645 genes differentially expressed between the beginning
and completion of the programme, with 196 genes up-
regulated and 449 genes down-regulated.
Pathway analysis
Biological pathway analysis identiﬁed a number of ca-
nonical pathways as being signiﬁcantly and consistently
modulated across patients with CAD compared with
control subjects (Figure 1a), and across the cardiac
rehabilitation exercise regime (Figure 1b). From (i)
the overall degree of modulation, (ii) the proportion
of differentially expressed genes in each pathway,
and (iii) biological relevance, further analyses were
focused on mitochondrial dysfunction and oxidative
phosphorylationpathways(alsoseeSupplementaryTable
S4 at http://www.clinsci.org/cs/119/cs1190335add.htm).
Within these pathways, expression of NDUFB3
[NADH dehydrogenase(ubiquinone)1β subcomplex 3],
UQCRQ (ubiquinol-cytochrome c reductase, complex
III subunit VII), COX7C (cytochrome c oxidase subunit
VIIc),andATP5I (ATPsynthase,H+ transporting,mito-
chondrialF0complex,subunitE)weregreaterinpatients
with CAD relative to control subjects. Completion of
the rehabilitation period was associated with a down-
regulation of the genes in these pathways: NDUFA1
[NADH dehydrogenase (ubiquinone) 1α subcomplex 1],
CASP3 (caspase 3), COX7C, ATP5I and ATP5L (ATP
synthase, H+ transporting, mitochondrial F0 complex,
subunit G) (see Supplementary Figures S1 and S2 at
http://www.clinsci.org/cs/119/cs1190335add.htm).qRT-
PCR conﬁrmed the up-regulation of NDUFB3 and
COX7C in patients with CAD and the down-regulation
of CASP3 and ATP5L following the rehabilitation
programme (Figure 2).
miRNA expression proﬁling
The miRNAs hsa-miR-140-3p (median signal intensity,
738 compared with 383; P=0.017) and hsa-miR-
182 (median signal intensity, 836 compared with 549;
P=0.093) were differentially regulated between patients
with CAD and control subjects (Figure 3a). Accordingly,
global analysis of predicted targets within the gene
expression dataset demonstrated signiﬁcantly reduced
expression of genes with target regions of hsa-miR-
140-3p and hsa-miR-182 (Figures 3b and 3c). Within
the post-surgery exercise groups, hsa-miR-92a (median
signal intensity, 4712 compared with 6250 respectively;
P<0.01) and hsa-miR-92b (median signal intensity,
1119 compared with 2163 respectively; P<0.01), which
have identical downstream mature sequences, were
differentially regulated between the beginning and
completion of the rehabilitation programme (Figure 4a).
Expression levels of predicted gene targets of hsa-
miR-92a and hsa-miR-92b were signiﬁcantly reduced
(Figure 4b). Moreover, predicted targets of hsa-miR-
92a and hsa-miR-92b include the genes NDUFA1 and
CASP3. The observed reduced expression of these genes
followingtherehabilitationprogrammeisconsistentwith
the increased expression of hsa-miR-92a and hsa-miR-
92b (Figure 2).
DISCUSSION
In the prsent study, we have successfully used gene
expression proﬁling in whole blood to establish genes
that are differentially regulated between patients with
CAD and control subjects, and whose expression is
modiﬁedfollowingacardiacrehabilitationprogrammein
patients with CAD. We have, for the ﬁrst time, identiﬁed
differentially regulated miRNAs in whole blood in
patients with CAD compared with healthy control
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Figure 1 Canonical pathways signiﬁcantly affected between (a) patients with CAD and healthy controls, and (b) patients
with CAD before and after a cardiac rehabilitation exercise programme, following a CABG procedure
The bars indicate the degree of signiﬁcance (y-axis) to which a given pathway is differentially modulated. ‘Threshold’ indicates the minimally accepted signiﬁcance
level. () The relative proportion of constituent members of a pathway signiﬁcantly differentially expressed. Oxidative phosphorylation and mitochondrial dysfunction
pathways were found to be signiﬁcantly and consistently regulated across both experimental groups. NFAT, nuclear factor of activated T-cells; LXR, liver X receptor;
PI3K, phosphoinositide 3-kinase; PPAR, peroxisome-proliferator-activated receptor; PKR, double-stranded-RNA-dependent protein kinase; RAR, retinoic acid receptor; RXR,
retinoid X receptor.
subjects. Among the biological pathways containing the
differentially expressed genes, we have identiﬁed those
involved in mitochondrial dysfunction and oxidative
phosphorylation as being the most consistently affected
and modulated.
Studies on gene expression in humans are particularly
difﬁcultduetothelimitedavailabilityoftissuefromwell-
phenotyped patients, and even more so from healthy
subjects. The use of blood as a ‘surrogate tissue’ that
can be obtained with a minimally invasive procedure is
therefore an attractive alternative. Although the majority
of studies have been performed in mononuclear cells
isolated from peripheral blood [30], there have been
reports on gene expression proﬁling in whole blood in
a number of human diseases, including Huntington’s
disease [4] and cancer [5,6]. Many different techniques
have been proposed to handle peripheral blood samples
prior to RNA isolation based on experimental design
[31]. We utilized the PAXgene Blood RNA system as
it provides a way to stabilize RNA immediately after
samplecollectionandfacilitatesstorageofthesamplesfor
a relatively long period of time without compromising
RNA integrity [31–34]. The straightforward procedure
of sample collection is an important condition for future
use of whole-blood gene expression proﬁling in clinical
practice. Most recently, whole-blood gene expression
proﬁling has also been applied to cardiovascular disease.
Sinnaeve et al. [35] showed a relationship between gene
expression proﬁles in whole blood with a CAD index
as a marker of the extent of disease. Our present
study adds important new features to this area of
research.
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Figure 2 Genes of the mitochondrial function pathway differentially expressed between (upper boxes) patients with CAD
and healthy controls, and (lower boxes) patients with CAD before and after a cardiac rehabilitation exercise programme,
following a CABG procedure
Upper boxes, up-regulation of genes in the mitochondrial function pathways in patients with CAD compared with healthy control subjects. Lower boxes, down-regulation
of genes in the mitochondrial function pathways following the cardiac rehabilitation programme. All genes were differentially expressed in microarray experiments (for
details see Supplementary Table S4 at http://www.clinsci.org/cs/119/cs1190335add.htm). P values and fold changes (FC) in the boxes refer to results from qRT-PCR
experiments (for details see Figures S1 and S2 at http://www.clinsci.org/cs/119/cs1190335add.htm). NDUFA1 and CASP3 are predicted targets of hsa-miR-92a and
hsa-miR-92b, whose expression was increased following the cardiac rehabilitation programme (see Figure 4).
Figure 3 miRNA expression in patients with CAD compared with healthy control subjects
(a) Heatmap analysis of miRNA expression in patients with CAD compared with healthy control subjects (P <0.10; signal intensity >500 intensity units). The analysis
shows relative ﬂuorescence from green (2-fold reduction) to red (2-fold increase) of each miRNA per individual (with an anonymous identiﬁer at the topo fe a c h
column). (b and c) Comparison of log ratios of hsa-miR-140-3p (b) and hsa-miR-182 (c) identiﬁed a signiﬁcant reduction in gene expression levels in predicted target
genes compared with non-targets.
In face of the multiplicity of differentially expressed
genes both between patients with CAD and controls,
andbetweenpre-andpost-cardiacrehabilitation,wehave
used pathway analysis to examine patterns of expression
rather than individual genes. Using this approach, we
wereabletointerpretdataonrelativelysmallfoldchanges
in gene expression, which may on their own be of limited
importance but, in combination, represent multiple hits
to speciﬁc pathways and may thereby affect, for example,
mitochondrial function. The ﬁnding that we were unable
to conﬁrm all differences in gene expression from the
microarray experiment with qRT-PCR may again be in
keeping with the existence of multiple changes, but of
relatively small magnitude, below the 2-fold limitation
of qRT-PCR. This pattern of numerous small changes
of expression could be reasonably expected in complex
cardiovascular traits such as CAD. Of particular note is
that the direction of these and other multiple ‘hits’ to
mitochondrial pathways, although small in magnitude,
reverse following exercise (Figure 2), indicating that this
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Figure 4 miRNA expression in patients with CAD before and after completion of the cardiac rehabilitation programme
(a) Heatmap analysis of miRNA expression in patients with CAD before and after completion of the cardiac rehabilitation programme (P <0.10; signal intensity
>500 intensity units). The analysis shows relative ﬂuorescence from green (2-fold reduction) to red (2-fold increase) of each miRNA per individual (with anonymous
identiﬁer at the top of each column). (b) Comparison of log ratios of hsa-miR-92a/b identiﬁed a signiﬁcant reduction in gene expression levels in predicted target
genes compared with non-targets.
intervention may offer speciﬁc beneﬁts in relation to
reducing oxidative stress in individuals recovering from
coronary surgery.
We have further corroborated our results by
simultaneously examining miRNA expression. Again,
interpretation of results, especially with regard to targets
of particular miRNAs, is challenging [25], but the
results support our main ﬁndings. The results on the
integrationofmiRNAswithexpressionoftheirpredicted
targets does indeed show a signiﬁcant generalized down-
regulation of these targets. This is in keeping with a
functional role of these molecules, although such a role
of miRNA in blood remains to be elucidated. We have,
however, shown that expression of hsa-miR-92a and hsa-
miR-92b are increased following cardiac rehabilitation,
which occurs in parallel with a conﬁrmed reduction
in expression of two of their predicted target genes.
Hsa-miR-92 has been found to be modulated in the
process of neointima formation in a rat model of vascular
injury [36], but to the best of our knowledge has not
yet been clearly implicated in the pathophysiology of
human cardiovascular disease. Although acknowledging
that hsa-miR-92a and hsa-miR-92b are likely to modify
a plethora of potential targets, and that the speciﬁc
interactions with NDUFA1 and CASP3 require further
detailed examination, it is nonetheless intriguing to
identify physiological candidates which are down-
regulated in concert with increased expression of these
miRNA. A further level of complexity of the regulation
of miRNA expression and activity can be seen by
the generation of the identical mature hsa-miR-92
miRNA from two different genetic loci. In relation
to target prediction and validation, the present study
has focused solely on that common mature sequence.
However, differential expression of the two pri-miRNAs
(potentially under the control of different up-stream
regulators) may occur in a heterogeneous manner in
different tissues, cells or compartments, offering even
more exquisite control of their relative activities. The
dynamic change of miRNA and gene expression towards
a ‘healthier’ proﬁle following cardiac rehabilitation is a
unique feature of our present study, supporting further
the relevance of the identiﬁed genes and miRNAs.
We acknowledge that our present ﬁndings only
provide initial evidence for a role of the discovered genes
and miRNAs. However, these ﬁndings are particularly
attractive as targets for intervention. Oxidative stress
has been implicated by a plethora of studies as
playing a key role in a range of cardiovascular diseases
[37–40]. Mitochondrial dysfunction, and particularly
generation of ROS by mitochondria, is an important
yet relatively novel mechanism contributing to the
development of oxidative stress and cardiovascular
disease [41,42]. We have recently shown that a speciﬁc
mitochondria-targetedantioxidant,MitoQ10,reducesthe
increased vascular superoxide generation in stroke-prone
spontaneously hypertensive rats and leads to a reduction
in BP (blood pressure) [43]. Our present results indicate
that there may be further options for mitochondria-
targeted therapies in human cardiovascular diseases
including CAD.
With regard to limitations of the present study, we
cannot exclude the possibility that the observations
obtained in the cardiac rehabilitation group are not,
at least to some extent, due to, for example, healing
of the sternotomy. Nonetheless, signiﬁcant changes
were observed in both gene expression and miRNA
proﬁling in the blood of these patients and, in particular,
speciﬁc pathways were identiﬁed as being modiﬁed
which were also shown to be changed in the CAD and
control comparison. Moreover, in this latter comparison,
these differences were determined in the patients with
CAD prior to undergoing surgery, illustrating that
dynamic changes in gene and miRNA expression can
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occur without the provocation caused by, for example,
signiﬁcant trauma such as surgery.
Our present study is also limited by the relatively
small sample sizes due to the signiﬁcant costs involved
in microarray studies. However, the careful selection
of patients and well-matched control subjects from a
larger cohort of well-characterized individuals reduced
the ‘noise’ in our expression proﬁling experiments. We
have further addressed this issue by studying a second set
of patients before and after completing the rehabilitation
programme using paired statistical analysis. We are
conﬁdent that, due to integration of these two datasets
and further analysis, together with miRNA expression
results, the identiﬁed genes and pathways are not only
valid, but may also be clinically relevant. It should also
be noted that the sample size in our study is equal to or
greater than that in other human global gene expression
proﬁling studies [44–46]. Clearly, the aim of the present
initial study was to identify such targets. Subsequent
validation of these targets in larger studies will be a
necessary step to conﬁrm their candidacy as biomarkers
and/or functionally relevant molecules in blood.
In summary, mRNA and miRNA expression proﬁling
in whole blood is a promising tool to discover genes
that determine cardiovascular phenotypes. The identiﬁed
genes and pathways are likely to play a key role in
the pathogenesis and progression of chronic CAD.
Moreover, we have identiﬁed biological pathways linked
to vascular function which appear to be modiﬁable by an
exercise intervention programme. Further elucidation of
thesemechanismswillcontributetoourunderstandingof
disease processes and ultimately lead to new therapeutic
and preventative strategies.
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Table S1 Clinical characteristics of patients with CAD and
healthy controls
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
BMI, body mass index; DBP, diastolic blood pressure; LDL, low-density lipoprotein;
HDL, high-density lipoprotein; SBP, systolic blood pressure.
Patients Healthy controls
Characteristic with CAD (n=12) (n=12) P value
Age (years) 66+ −11 59+ −7N S
Male gender (n)1 2 1 2
SBP (mmHg) 130+ −23 135+ −22 NS
DBP (mmHg) 78+ −13 85+ −12 NS
Heart rate (beats/min) 58+ −57 1 + −15 <0.05
BMI (kg/m2)2 6 + −32 7 + −3N S
Waist/hip ratio 0.90+ −0.04 0.90+ −0.10 NS
Active smoker (n)0 0
Type 2 diabetes mellitus (n)0 0
Hypertension (n) 9 (75%) 0
Total cholesterol (mmol/l) 3.8+ −0.6 5.1+ −0.5 <0.05
LDL-cholesterol (mmol/l) 1.9+ −0.7 3.4+ −0.5 <0.05
HDL-cholesterol (mmol/l) 1.1+ −0.3 1.2+ −0.2 NS
CRP (mg/l) 7.6+ −11.0 1.5+ −0.9 NS
Medication (n)
Antiplatelet 11 2 <0.001
β-Blocker 12 0 <0.001
Statin 11 0 <0.001
ACEI or ARB 4 0 0.093
Calcium channel blocker 3 0 NS
Table S2 Clinical characteristics of patients with CAD
before and after taking part in the cardiac rehabilitation
programme
Medication was not changed after compared with before participation in the
rehabilitation programme. ACEI, angiotensin-converting enzyme inhibitor; ARB,
angiotensin receptor blocker; BMI, body mass index; DBP, diastolic blood pressure;
LDL, low-density lipoprotein; HDL, high-density lipoprotein; SBP, systolic blood
pressure.
Characteristic Before (n=10) After (n=10) P value
Age (years) 69+ −9
Male gender 10
SBP (mmHg) 135+ −20 135+ −23 NS
DBP (mmHg) 77+ −87 6 + −9N S
Heart rate (beats/min) 71+ −11 67+ −12 NS
BMI (kg/m2) 27.4+ −2.4 28.0+ −2.6 NS
Waist/hip ratio 0.96+ −0.03 0.96+ −0.04 NS
Active smoker 0 0
Type 2 diabetes mellitus 0 0
Hypertension (n) 8 (80%) 8 (80%)
Total cholesterol (mmol/l) 4.0+ −0.7 4.0+ −0.7 NS
LDL-cholesterol (mmol/l) 2.2+ −0.7 2.1+ −0.8 NS
HDL-cholesterol (mmol/l) 1.2+ −0.2 1.4+ −0.3 0.052





ACEI or ARB 4
Calcium channel blocker 0
1 These authors contributed equally to this work.
Correspondence: Dr Christian Delles (c.delles@clinmed.gla.ac.uk).
C   The Authors Journal compilation C   2010 Biochemical SocietyC. Taurino and others
Figure S1 TaqMan® qRT-PCR analysis of expression of candidate genes in healthy controls and patients with CAD
∗P <0.05 compared with control (n=12 per group).
Figure S2 TaqMan® qRT-PCR analysis of expression of candidate genes in patients with CAD before and after an exercise
rehabilitation programme
∗P <0.05 compared with pre-exercise (n=10 per group).
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Table S4 Differentially expressed genes (microarray data) between patients with CAD and healthy control subjects
(a and c), and in patients with CAD pre- and post-cardiac rehabilitation (b and d), assigned to oxidative phosphory-
lation (a and b) and mitochondrial dysfunction (c and d) pathways
(a) Oxidative phosphorylation: patients with CAD compared with healthy controls
Gene symbol Entrez Gene name Illumina FDR (q value) Fold change Entrez Gene ID
ATP5C1 ATP synthase, H+ transporting,
mitochondrial F1 complex γ
polypeptide 1
ILMN_1701269 0.049 1.232 509
ATP5I ATP synthase, H+ transporting,
mitochondrial F0 complex, subunit E
ILMN_1726603 0.011 1.356 521
COX7B Cytochrome c oxidase subunit VIIb ILMN_2184049 0.005 1.346 1349
COX7C (includes EG:1350) Cytochrome c oxidase subunit VIIc ILMN_1798189 0.02 1.266 1350
NDUFA4 NADH dehydrogenase (ubiquinone) 1α
subcomplex 4, 9 kDa
ILMN_1751258 0.007 1.362 4697
NDUFB3 NADH dehydrogenase (ubiquinone) 1β
subcomplex 3, 12 kDa
ILMN_2119945 0.002 1.441 4709
UQCRQ Ubiquinol-cytochrome c reductase,
complex III subunit VII, 9.5 kDa
ILMN_1666471 0 1.484 27089
(b) Oxidative phosphorylation: pre- compared with post-rehabilitation in patients with CAD
Symbol Entrez Gene name Illumina FDR (q value) Fold change Entrez Gene ID
ATP5I ATP synthase, H+ transporting,
mitochondrial F0 complex, subunit E
ILMN_1772506 0.007 −1.298 521
ATP5J ATP synthase, H+ transporting,
mitochondrial F0 complex, subunit F6
ILMN_1772929 0.009 −1.31 522
ATP5L ATP synthase, H+ transporting,
mitochondrial F0 complex, subunit G
ILMN_1812638 0 −1.483 10632
ATP5O ATP synthase, H+ transporting,
mitochondrial F1 complex, O subunit
ILMN_1791332 0.028 −1.205 539
ATP6V1D ATPase, H+ transporting, lysosomal 34
kDa, V1 subunit D
ILMN_1797310 0.006 −1.28 51382
COX7C (includes EG:1350) cytochrome c oxidase subunit VIIc ILMN_1798189 0 −1.585 1350
IHPK2 Inositol hexakisphosphate kinase 2 ILMN_1683328 0.033 −1.186 51447
NDUFA1 NADH dehydrogenase (ubiquinone) 1α
subcomplex 1, 7.5 kDa
ILMN_1784286 0.005 −1.315 4694
NDUFB2 NADH dehydrogenase (ubiquinone) 1β
subcomplex 2, 8 kDa
ILMN_2117330 0.046 −1.198 4708
NDUFB3 NADH dehydrogenase (ubiquinone) 1β
subcomplex 3, 12 kDa
ILMN_2119945 0.002 −1.315 4709
NDUFB6 NADH dehydrogenase (ubiquinone) 1β
subcomplex 6, 17 kDa
ILMN_1763147 0.03 −1.207 4712
NDUFS5 NADH dehydrogenase (ubiquinone) Fe-S
protein 5, 15 kDa (NADH-coenzyme Q
reductase)
ILMN_1776104 0.005 −1.332 4725
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Table S4 Continued
(c) Mitochondrial dysfunction: patients with CAD compared with healthy controls
Symbol Entrez Gene name Illumina FDR (q value) Fold change Entrez Gene ID
ATP5C1 ATP synthase, H+ transporting,
mitochondrial F1 complex, gamma
polypeptide 1
ILMN_1701269 0.049 1.232 509
COX7B Cytochrome c oxidase subunit VIIb ILMN_2184049 0.005 1.346 1349
COX7C (includes EG:1350) Cytochrome c oxidase subunit VIIc ILMN_1798189 0.02 1.266 1350
NDUFA4 NADH dehydrogenase (ubiquinone) 1α
subcomplex, 4, 9 kDa
ILMN_1751258 0.007 1.362 4697
NDUFB3 NADH dehydrogenase (ubiquinone) 1β
subcomplex, 3, 12 kDa
ILMN_2119945 0.002 1.441 4709
(d) Mitochondrial dysfunction: pre- compared with post-rehabilitation in patients with CAD
Symbol Entrez Gene name Illumina FDR (q-value) Fold change Entrez Gene ID
APH1A (includes EG:51107) Anterior pharynx defective 1 homologue
A( Caenorhabditis elegans)
ILMN_2398388 0.026 1.22 51107
ATP5J ATP synthase, H+ transporting,
mitochondrial F0 complex, subunit F6
ILMN_1772929 0.009 −1.31 522
CASP3 Caspase 3, apoptosis-related cysteine
peptidase
ILMN_2388155 0.006 −1.265 836
CASP8 Caspase 8, apoptosis-related cysteine
peptidase
ILMN_1673757 0.001 −1.449 841
CAT Catalase ILMN_1651705 0.041 −1.302 847
COX7C (includes EG:1350) Cytochrome c oxidase subunit VIIc ILMN_1798189 0 −1.585 1350
NDUFB2 NADH dehydrogenase (ubiquinone) 1β
subcomplex 2, 8 kDa
ILMN_2117330 0.046 −1.198 4708
NDUFB3 NADH dehydrogenase (ubiquinone) 1β
subcomplex 3, 12 kDa
ILMN_2119945 0.002 −1.315 4709
NDUFB6 NADH dehydrogenase (ubiquinone) 1β
subcomplex 6, 17 kDa
ILMN_1763147 0.03 −1.207 4712
NDUFS5 NADH dehydrogenase (ubiquinone) Fe-S
protein 5, 15 kDa (NADH-coenzyme Q
reductase)
ILMN_1776104 0.005 −1.332 4725
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